Learn About Acute Megakaryoblastic Leukemia

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Acute Megakaryoblastic Leukemia Local Doctors?
TG
Dr. Tanja A. Gruber
Pediatrics | Pediatric Hematology Oncology | Hematology Oncology
Elite
Highly rated in
7
conditions
Pediatrics
Pediatric Hematology Oncology
Hematology Oncology

725 Welch Rd 
Palo Alto, CA 94304

Tanja Gruber is a Pediatrics specialist and a Pediatric Hematologist Oncology doctor in Palo Alto, California. Dr. Gruber has been practicing medicine for over 19 years and is rated as an Elite doctor by MediFind in the treatment of Acute Megakaryoblastic Leukemia. She is also highly rated in 7 other conditions, according to our data. Her top areas of expertise are Acute Megakaryoblastic Leukemia, Childhood Acute Myeloid Leukemia, Leukemia, and Acute Myeloid Leukemia. She is licensed to treat patients in Tennessee and California. Dr. Gruber is currently accepting new patients.

View Profile
SA
Souichi Adachi
Elite
Highly rated in
22
conditions

University Of Tokyo

Kyoto University 
Kyoto, JP 

Souichi Adachi is in Kyoto, Japan. Adachi is rated as an Elite expert by MediFind in the treatment of Acute Megakaryoblastic Leukemia. They are also highly rated in 22 other conditions, according to our data. Their top areas of expertise are Childhood Acute Myeloid Leukemia, Acute Megakaryoblastic Leukemia, Leukemia, and Acute Myeloid Leukemia.

View Profile
 
 
 
 
Learn about our expert tiers
Learn more
EI
Etsuro Y. Ito
Elite
Highly rated in
25
conditions

Hirosaki University Graduate School Of Medicine

Waseda University 
Tokyo, JP 16284

Etsuro Ito is in Tokyo, Japan. Ito is rated as an Elite expert by MediFind in the treatment of Acute Megakaryoblastic Leukemia. They are also highly rated in 25 other conditions, according to our data. Their top areas of expertise are Acute Megakaryoblastic Leukemia, Down Syndrome, Aase Syndrome, and Pure Red Cell Aplasia.

View Profile
View All Doctors
What are the Latest Advances for Acute Megakaryoblastic Leukemia?
Hematological neoplasia associated with primary mediastinal germ-cell tumor treated with hematopoietic stem cell transplantation.
Condition: Hematological Neoplasia Associated with Primary Mediastinal Germ-Cell Tumor
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Treatment Used: Hematopoietic Stem Cell Transplantation
Number of Patients: 1
Published: November 04, 2021
View publication
Summary: Hematological neoplasia associated with primary mediastinal germ-cell tumor treated with hematopoietic stem cell transplantation.
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
Journal: International journal of molecular sciences
Published: July 02, 2021
View publication
Summary: Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
Tired of the same old research?
Check Latest Advances
Clinical features and prognosis of pediatric acute megakaryocytic leukemia.
Journal: Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
Published: June 16, 2021
View publication
Summary: Clinical features and prognosis of pediatric acute megakaryocytic leukemia.
View All Latest Advances
What are the latest Acute Megakaryoblastic Leukemia Clinical Trials?
A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML)
Who is this study for: Adult patients with Acute Myeloid Leukemia
Status: Active, not recruiting
Start Date: April 2008
Intervention Type: Drug, Other
Study Drugs: Cytarabine, Intensol, Daunorubicin
Phase: Phase 3
View Trial
Summary: The purpose of this study is to compare the effects, good and/or bad, of a standard chemotherapy regimen for AML that includes the drugs daunorubicin and cytarabine combined with or without midostaurin (also known as PKC412), to find out which is better. This research is being done because it is unknown whether the addition of midostaurin to chemotherapy treatment is better than chemotherapy treat...
Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase II Trial of Azacitidine (NSC-102816) Plus Gemtuzumab Ozogamicin (NSC-720568) as Induction and Post-Remission Therapy in Patients of Age 60 and Older With Previously Untreated Non-M3 Acute Myeloid Leukemia
Who is this study for: Adult patients with Acute Myeloid Leukemia
Status: Active, not recruiting
Start Date: December 1, 2008
Intervention Type: Drug
Study Drugs: Azacitidine, Gemtuzumab Ozogamicin
Phase: Phase 2
View Trial
Summary: This phase II trial is studying the side effects of giving azacitidine together with gemtuzumab ozogamicin to see how well it works in treating older patients with previously untreated acute myeloid leukemia. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Azacitidine may also...
View All Clinical Trials